VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients
pharmaceutical investing VBI Vaccines Announces Dosing of First Patient in Phase 1/2a Clinical Study of VBI-1901
pharmaceutical investing VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
Silver Hammer Closes CDN$3,913,617 Non-Brokered Private Placement Pursuant to Listed Issuer Exemption
